Gene symbol | WT1 | Synonyms | AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33 | Type of gene | protein-coding |
Chromosome | 11 | Map location | 11p13 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
Description | WT1 transcription factor |
GTO ID | GTC0612 |
Trial ID | ISRCTN11622375 |
Disease | Myeloid Leukemia |
Altered gene | WT1 |
Therapeutic/Target gene | Target gene |
Therapy | TCR-T cell |
Treatment | WT1 TCR-T cells |
HLA | HLA-A*02:01 |
Phase | Phase1|Phase2 |
Recruitment status | Completed |
Title | A phase I/II safety and toxicity study on the use of WT1 TCR gene therapy for adult patients with acute and chronic myeloid leukaemia |
Year | 2010 |
Country | United Kingdom |
Company sponsor | University College London (UCL) (UK) |
Other ID(s) | 2006-004950-25|NCT01621724|D-00272-CT2014001 |
Vector information | |||
|
Cohort1: dose level 1 | |||||||||||||||||
|
|||||||||||||||||
Cohort2: dose level 2 | |||||||||||||||||
|